mojoapp.bsky.social

Cigna just said more employers are no longer covering weight-loss GLP-1s. Their words, per Becker's: "a slight downtick." A "modest headwind." Not a collapse. A cut aimed at one indication.

Sources: Becker's (Cigna "slight downtick" / "modest headwind"): www.beckerspayer.com/payer/cigna... Bloomberg (employers trimming obesity drug benefits): www.bloomberg.com/news/articl... CNBC on IFEBP 2026 pulse (36% / 60% / 11.4% / 9%): www.cnbc.com/2026/07/08/...

Cigna just said more employers are no longer covering weight-loss GLP-1s. Their words, per Becker's: "a slight downtick." A "modest headwind." Not a collapse. A cut aimed at one indication.

Cigna already moved on its own workers: Wegovy and Zepbound for weight loss ended July 1. Last fill was June 30. Self-pay entry: ~$199/mo Wegovy, ~$299/mo Zepbound (starter doses). STAT's catch: that spend often won't hit your deductible, and you lose group pricing.

Cigna just said more employers are no longer covering weight-loss GLP-1s. Their words, per Becker's: "a slight downtick." A "modest headwind." Not a collapse. A cut aimed at one indication.

mojo ran the numbers. Per CNBC on IFEBP's pulse of ~300 U.S. plans: • 36% cover diabetes + weight loss (flat vs 2025; was 34% in 2024) • plans that cover diabetes only: 55% → 60% The squeeze is weight loss. Not the whole drug class.

Fit Boxing is one of those games that sounds ridiculous until you've been throwing punches in your living room for 15 minutes straight. No gym. No outfit. Still cardio. mojo tracks GLP-1 users who actually stick to movement. It's almost never the 5AM gym plan.

70% of people who stop GLP-1s regain most of their lost weight within 18 months. A new minimally invasive procedure might change that.

Still investigational, no FDA approval yet. But the direction matters — post-GLP-1 maintenance might not be limited to "stay on drugs forever" vs "white-knuckle it alone."

70% of people who stop GLP-1s regain most of their lost weight within 18 months. A new minimally invasive procedure might change that.

First blinded, randomized, sham-controlled trial presented at DDW 2026. 45 patients who'd lost ≥15% body weight on tirzepatide stopped the drug, then received either duodenal mucosal resurfacing (controlled heat to remove damaged intestinal lining, letting healthy tissue regrow) or a sham procedure.

Mayo Clinic just published the first head-to-head comparison of bariatric surgery (gastric bypass, sleeve gastrectomy) vs GLP-1 meds on cardiovascular outcomes. Both work. Surgery showed greater long-term risk reduction.

If you're BMI 35+ with cardiovascular risk factors, this study is worth bringing to your next doctor's appointment.

Mayo Clinic just published the first head-to-head comparison of bariatric surgery (gastric bypass, sleeve gastrectomy) vs GLP-1 meds on cardiovascular outcomes. Both work. Surgery showed greater long-term risk reduction.

Until now, surgery and GLP-1s each had their own evidence base. Nobody compared them directly. That's a big gap when patients are choosing between "a needle" and "the OR." More data = better decisions.

Mayo Clinic just published the first head-to-head comparison of bariatric surgery (gastric bypass, sleeve gastrectomy) vs GLP-1 meds on cardiovascular outcomes. Both work. Surgery showed greater long-term risk reduction.

GLP-1 is an accelerator. Not an autopilot. Think of it as a multiplier for your habits. Medication (100) × Habits (0) = 0. Rely entirely on the shot, and you're just losing muscle and borrowing time before the weight comes back. Start small: • Eat protein and fiber first

GLP-1s are quietly rewiring the $40 billion U.S. cannabis market. The target is the munchies. Post-cannabis hunger drives a massive chunk of dispensary sales. But GLP-1 users are noticing something strange. The urge just vanishes. Not "I ate less." The craving never shows up.

These meds aren't just managing weight. They're turning off the constant cravings for dopamine. What random craving completely vanished for you since starting?

GLP-1s are quietly rewiring the $40 billion U.S. cannabis market. The target is the munchies. Post-cannabis hunger drives a massive chunk of dispensary sales. But GLP-1 users are noticing something strange. The urge just vanishes. Not "I ate less." The craving never shows up.

Novo Nordisk just partnered with OpenAI to deploy AI across drug discovery, manufacturing, and commercial operations. Not a pilot. Full deployment. The context: Eli Lilly got oral GLP-1 Foundayo approved. Zepbound is gaining ground. Novo is behind.

The pharma arms race just moved to silicon. Would you trust an AI-designed drug more or less than a traditional one?

Novo Nordisk just partnered with OpenAI to deploy AI across drug discovery, manufacturing, and commercial operations. Not a pilot. Full deployment. The context: Eli Lilly got oral GLP-1 Foundayo approved. Zepbound is gaining ground. Novo is behind.

GLP-1s cut U.S. adult obesity from 40% to 37% in two years. The first real drop in decades. Then the bill arrived. 🧵

12% of U.S. adults take a GLP-1. The meds are doing exactly what they promised. But the people who need them most are being cut off first. Low-income patients on Medicaid.

GLP-1s cut U.S. adult obesity from 40% to 37% in two years. The first real drop in decades. Then the bill arrived. 🧵

Spending on these meds jumped from $13.7B to $71.7B in five years. A 5x spike. States panicked.

"I've had plastic surgery over the years, and I use Mounjaro. Sorry to whoever feels let down." Amy Schumer went on Instagram and told everyone exactly how she lost 50 lbs. Not to look hot. To survive.

No pretending it was willpower. mojo's seen too many people quit after one bad try. Three meds, three very different reactions. Your body decides, not you.

"I've had plastic surgery over the years, and I use Mounjaro. Sorry to whoever feels let down." Amy Schumer went on Instagram and told everyone exactly how she lost 50 lbs. Not to look hot. To survive.

Then came the weight loss. Three tries before anything worked. Ozempic → nauseous holding her son, stopped Wegovy → vomiting so bad she couldn't lift her head, lost 30 lbs but couldn't function, stopped Mounjaro → her body finally accepted it

"I've had plastic surgery over the years, and I use Mounjaro. Sorry to whoever feels let down." Amy Schumer went on Instagram and told everyone exactly how she lost 50 lbs. Not to look hot. To survive.

She wanted to tell everyone to go to hell. But scrolling through, she noticed something different. Doctors in the comments saying this wasn't weight gain. It looked like Cushing syndrome. Cortisol through the roof. Fatal if untreated.

"I've had plastic surgery over the years, and I use Mounjaro. Sorry to whoever feels let down." Amy Schumer went on Instagram and told everyone exactly how she lost 50 lbs. Not to look hot. To survive.

Stared at your belly for 3 mins and couldn't press the button? You're up against your brain's natural defense mechanism. 3 facts to ease your fear: ① Tiny needle: 4mm is as thin as 2 hairs. Hits fat, not nerves. Barely felt.

If your GLP-1 isn't working, you didn't fail. A new 23andMe study of 28,000 people just confirmed it. Variants in your GLP-1R and GIPR genes directly affect your weight loss and your side effects.

Clinical trials already hinted that 10-15% of people are low responders. Now we have the receipts. Genetics aren't destiny. Dose, habits, and duration still matter. But if the scale isn't moving, stop blaming your willpower. It's just biology.